Treatment of NF1-related plexiform neurofibroma with trametinib; a single arm, open-label trial with the goals of volumetric partial remission and pain relief
Phase of Trial: Phase II
Latest Information Update: 13 Sep 2019
Price : $35 *
At a glance
- Drugs Trametinib (Primary)
- Indications Plexiform neurofibroma
- Focus Therapeutic Use
- Acronyms plexifpc
- 21 Dec 2018 Planned End Date changed from 1 May 2022 to 1 Jul 2022.
- 21 Dec 2018 Planned primary completion date changed from 1 May 2022 to 1 Jul 2022.
- 26 Sep 2018 New trial record